| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
This compound targets the melanocortin-4 receptor (MC-4R) with high potency and selectivity. It exhibits binding affinities of 0.55+/-0.06 nM for human MC-4R, 16.78+/-1.53 nM for MC-1R, 56.79+/-4.66 nM for MC-3R, and <500 nM for MC-5R. MC-4R is a G-protein coupled receptor involved in the regulation of energy homeostasis and feeding behavior.
|
|---|---|
| ln Vitro |
In vitro, this peptide shows sub-nanomolar potency at the MC-4 receptor. It activates MC-4R with high selectivity over other melanocortin receptor subtypes. The compound is used to study melanocortin receptor pharmacology and the role of MC-4R in energy balance and feeding regulation.
|
| ln Vivo |
In vivo, MC-4R agonists such as this compound are studied for their effects on food intake and body weight regulation. Activation of MC-4R in the hypothalamus leads to reduced food intake and increased energy expenditure. The compound may be used in research on obesity and related metabolic disorders.
|
| Enzyme Assay |
Receptor binding assays for this compound use membrane preparations from cells expressing human MC-1R, MC-3R, MC-4R, or MC-5R. Radiolabeled MSH or a related ligand is incubated with varying concentrations of the test peptide, and binding affinities (Ki) are calculated from competition binding curves.
|
| Cell Assay |
Cellular assays for this compound typically use cell lines expressing melanocortin receptors. Cells are treated with the peptide, and cAMP accumulation is measured as a readout of receptor activation. Potency (EC₅0) is calculated from dose-response curves.
|
| Animal Protocol |
In vivo studies with this compound are conducted in rodent models. The peptide is typically administered via intraperitoneal or intracerebroventricular injection. Food intake, body weight, and metabolic parameters are monitored. Effects on energy expenditure and thermogenesis may also be assessed.
|
| ADME/Pharmacokinetics |
As a peptide, this compound is expected to have a short half-life due to proteolytic degradation. The disulfide bridges provide some stability to the peptide structure. Standard peptide storage and handling procedures apply. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicity data for this compound are limited. MC-4R agonists are generally well-tolerated, though chronic activation may have effects on blood pressure and other physiological parameters. Standard safety precautions for laboratory handling apply.
|
| References | |
| Additional Infomation |
This compound is a research-use peptide and is not approved for therapeutic applications. It is also known as LY2112688 trifluoroacetate. The peptide is a beta-MSH-derived analog used to study melanocortin receptor pharmacology and the regulation of energy homeostasis. It is available from multiple research suppliers.
|
| Molecular Formula |
C51H70N18O11S2
|
|---|---|
| Molecular Weight |
1177.36000
|
| Exact Mass |
1176.51
|
| CAS # |
819048-44-7
|
| PubChem CID |
11240266
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.762
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
35
|
| Heavy Atom Count |
82
|
| Complexity |
2240
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(N[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CS)=O)CC1=CNC2=CC=CC=C12)=O)CCCNC(N)=N)=O)CC3=CC=CC=C3)=O)CC4=CN=CN4)=O)CCC(O)=O)=O)CS)=O)CCCNC(N)=N)=O
|
| InChi Key |
ZUGUOZWTPYJYJW-ZSTGMXRXSA-N
|
| InChi Code |
InChI=1S/C51H72N18O11S2/c1-27(70)62-33(13-7-17-58-50(53)54)43(74)69-40(25-82)49(80)64-35(15-16-41(71)72)45(76)67-38(21-30-23-57-26-61-30)48(79)65-36(19-28-9-3-2-4-10-28)46(77)63-34(14-8-18-59-51(55)56)44(75)66-37(47(78)68-39(24-81)42(52)73)20-29-22-60-32-12-6-5-11-31(29)32/h2-6,9-12,22-23,26,33-40,60,81-82H,7-8,13-21,24-25H2,1H3,(H2,52,73)(H,57,61)(H,62,70)(H,63,77)(H,64,80)(H,65,79)(H,66,75)(H,67,76)(H,68,78)(H,69,74)(H,71,72)(H4,53,54,58)(H4,55,56,59)/t33-,34+,35+,36-,37+,38+,39+,40+/m1/s1
|
| Chemical Name |
(4S)-4-[[(2R)-2-[[(2R)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-sulfanylpropanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8494 mL | 4.2468 mL | 8.4936 mL | |
| 5 mM | 0.1699 mL | 0.8494 mL | 1.6987 mL | |
| 10 mM | 0.0849 mL | 0.4247 mL | 0.8494 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
